Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152908 | 0.85 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1KDM4ENPC1GAA | |
| SCHEMBL20379117 | 0.72 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1CD44KDM4ENPC1 | |
| SCHEMBL29483286 | 0.70 | CNR2 (0.43) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL560128 | 0.70 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1CD44HPGDSMN1; SMN2 | |
| SCHEMBL7736978 | 0.69 | — | — | |
| SCHEMBL6348373 | 0.69 | CASP3 (0.35) | — | |
| SCHEMBL6135309 | 0.69 | GPR55 (0.39) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL2679546 | 0.69 | RAB9A (0.48) | ALDH1A1L3MBTL1KDM4ENPC1GAA | |
| SCHEMBL4954846 | 0.69 | IDO1 (0.43) | ALDH1A1KDM4ENPC1GAAHPGD | |
| SCHEMBL5575870 | 0.68 | NPC1 (0.55) | ALDH1A1L3MBTL1CD44KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164252-A1 | ISOTHERMAL NUCLEIC ACID DETECTION ASSAYS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-31 | — | — | WO | claimed |
| CN-109342381-A | A kind of fluorescent dyeing reagent | 广州往圣生物科技有限公司 | 2019-02-15 | — | — | CN | claimed |
| US-9915665-B2 | High-throughput system and method for identifying antibodies having specific antigen binding activities | ABBVIE INC. (US) | 2018-03-13 | — | — | US | claimed |
| WO-2017027062-A1 | PROBES FOR RAPID AND SPECIFIC DETECTION OF MYCOBACTERIA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-02-16 | — | — | WO | claimed |
| US-20170044593-A1 | PROBES FOR RAPID AND SPECIFIC DETECTION OF MYCOBACTERIA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-02-16 | — | — | US | claimed |
| EP-2938636-A2 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES | AbbVie Inc. (US) | 2015-11-04 | — | — | EP | claimed |
| US-20140243228-A1 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES | ABBVIE, INC. (US) | 2014-08-28 | — | — | US | claimed |
| US-8816095-B2 | Na channels, disease, and related assays and compositions | GEORGETOWN UNIVERSITY (US) | 2014-08-26 | — | — | US | claimed |
| WO-2014106004-A2 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES | ABBVIE, INC. (US) | 2014-07-03 | — | — | WO | claimed |
| US-20140024137-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS | NUBAD LLC | 2014-01-23 | — | — | US | claimed |
| US-20130344588-A1 | DEVICES AND METHODS FOR CONCENTRATION AND ANALYSIS OF FLUIDS | MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) | 2013-12-26 | — | — | US | claimed |
| WO-2013070943-A2 | SMALL MOLECULE SCREEN FOR INHIBITORS OF NFAT:AP-1:DNA INTERACTIONS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-05-16 | — | — | WO | claimed |
| EP-2330908-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | Georgetown University (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010019967-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | claimed |
| WO-2026107198-A1 | ANTIBODY BIOMARKER TO DIAGNOSE IDIOPATHIC INFLAMMATORY MYOPATHIES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125675-A1 | DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY | H LEE MOFFITT CANCER CENTER AND RESEARCH INST INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731758-A2 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY | The Methodist Hospital (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-0478682-A1 | DETECTION OF FUNGAL GROWTH. | ASSURANCE COMPAGNIET BALTICA A (DK) | 1992-04-08 | — | — | EP | disclosed |
| WO-1990015879-A1 | DETECTION OF FUNGAL GROWTH | ASSURANCE-COMPAGNIET BALTICA A/S (DK) | 1990-12-27 | — | — | WO | disclosed |
| US-4361638-A | AMORPHOUS SILICON AND CARBON BASE MATERIAL DOPED WITH HYDROGEN AND FLUORINE | FUJI PHOTO FILM CO., LTD. (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044593-A1 | PROBES FOR RAPID AND SPECIFIC DETECTION OF MYCOBACTERIA | DPEP1, MRPL21, RCE1 | ALDH1A1 701/4885L3MBTL1 284/4885CD44 3676/4885 |
| US-20260125675-A1 | DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY | PDCD1LG2, TRMT1L, TTLL12 | ALDH1A1 3647/4885L3MBTL1 13/4885CD44 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.